Search research articles
Contact Us
Filters
Showing results (161-170 of 190) with videos related to
Page
of 19
Sort By:
Plos One
|
June 11, 2021
Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy
Margot Geens, Sofie Stappers, Heleen Konings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2002
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923
Andrea Ardizzoni, Vivianne C G Tjan-Heijnen, Pieter E Postmus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 1, 2016
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
Valerie W Rusch, Kari Chansky, Hedy L Kindler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 3, 2008
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program
Paul Taylor, Bruno Castagneto, Graham Dark, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 2, 2013
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer
Luis Paz-Ares, Beatrix Bálint, Richard H de Boer, et al.
Journal of the National Cancer Institute
|
March 22, 2007
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer
Jan P van Meerbeeck, Gijs W P M Kramer, Paul E Y Van Schil, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 7, 2002
Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy
Suresh Senan, Sjaak Burgers, Michael J Samson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2019
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study
Dean A Fennell, Paul Baas, Paul Taylor, et al.
The European Respiratory Journal
|
June 6, 2024
A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205
Jo Raskin, Veerle Surmont, Alexander P W M Maat, et al.
Molecular Oncology
|
December 1, 2022
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition
Sabine Paternot, Eric Raspé, Clément Meiller, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 190) with videos related to
Sort By:
Page
of 19
Plos One
|
June 11, 2021
Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy
Margot Geens, Sofie Stappers, Heleen Konings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2002
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923
Andrea Ardizzoni, Vivianne C G Tjan-Heijnen, Pieter E Postmus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 1, 2016
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
Valerie W Rusch, Kari Chansky, Hedy L Kindler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 3, 2008
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program
Paul Taylor, Bruno Castagneto, Graham Dark, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 2, 2013
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer
Luis Paz-Ares, Beatrix Bálint, Richard H de Boer, et al.
Journal of the National Cancer Institute
|
March 22, 2007
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer
Jan P van Meerbeeck, Gijs W P M Kramer, Paul E Y Van Schil, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 7, 2002
Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy
Suresh Senan, Sjaak Burgers, Michael J Samson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2019
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study
Dean A Fennell, Paul Baas, Paul Taylor, et al.
The European Respiratory Journal
|
June 6, 2024
A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205
Jo Raskin, Veerle Surmont, Alexander P W M Maat, et al.
Molecular Oncology
|
December 1, 2022
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition
Sabine Paternot, Eric Raspé, Clément Meiller, et al.
Page
of 19